CFDA Approves Gilupi CTC Device
The China Food and Drug Administration approved the Gilupi CellCollector, a circulating tumor cell isolation device.
The firm credited its strategic partner and largest shareholder Hebei Viroad Biotechnology for assistance with the CFDA approval. Gilupi plans to launch the product in China using Viroad’s experience with the Chinese market.
The CellCollector was the first in vivo CTC isolation device to secure the CE-mark.